SYMPOSIA
Symposium I: "Emergent Drug Development Approaches and Opportunities"
Co-Chairman : Lawrence Vernetti, Ph.D. Marina Seme-Nelson, Ph.D.
Marina Seme-Nelson, Ph.D.
Drug Development Leader, Covance Inc., Madison, WITitle: Bridging the Gap: IND to FIH and Beyond
Stephanie C. Oestreich, MPA
EVP, Head BRIDGEs Partnerships North America, EvotecTitle: Path to IND – How to Use Partners to Create Valuable Data for a Startup
Adam Simon, Ph.D.
Scientist - AI & Chemistry
Qulab Inc., Los Angeles, CATitle: AI-Automated De Novo Small Molecule Design
Ravindra Peravali, Ph.D.
Head, Screening Center, Institute of Toxicology and Genetics (ITG), Karlsruhe Institute of Technology, GermanyTitle: Using zebrafish embryonic and larval behavior for drug discovery and testing
Michael Graziano, Ph.D.
Chief Scientific Officer, TARA Biosystems, Inc., New York, NYTitle: Cardiotype SM Engineered Cardiac Tissues: An iPSC Derived Human-Relevant Model for Drug Discovery and Development
Robert Ricciardi, Ph.D.
Professor & Chair, Department of Microbiology, University of Pennsylvania, PATitle: Developing a Novel Drug to Treat Herpes Ocular Keratitis, the Leading Cause of Ocular Blindness in the World
Helen Yu, LLB, JD, Ph.D
Associate Director, Centre for Advanced Studies in Biomedical Innovation Law, University of Copenhagen, DenmarkTitle: Leveraging Research Failures to Accelerate Drug Discovery and Development
Taleb H. Al-Tel, Ph.D
Director, Research Institute for Medical & Health Sciences, University of Sharjah, UAETitle: The Visual Seeing of the Third Dimension as a Powerful Tool for Drug Discovery Campaign: Discovery of Novel Lead Drug Candidates for Cancer Immunotherapy
Symposium II: "Emerging Drug Development for Cannabis"
Co-Chairman : Ethan Russo, M.D. Dana M. Lambert, Ph.D.
David M. Lovinger, Ph.D.
Chief, Laboratory for Integrative Neuroscience, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MDTitle: Cannabinoid Drugs and Endocannabinoids in Behavioral Disorders and Addiction
Igor Kovalchuk, M.D., Ph.D.
Professor, Department of Biological Sciences University of LethbridgeCanada
Title: Cannabinoid Drugs and Endocannabinoids in Behavioral Disorders and Addiction
Klaus Gawrisch, Ph.D.
Chief, Section of NMR, Chief, Laboratory of Membrane Biochemistry and Biophysics, NIAAA, NIH, Bethesda, MDTitle: Pharmacology of cannabinoid ligands and ligand-induced changes of receptor structure
Dana M. Lambert, B.Sc.(Pharm), R.Ph., Ph.D.
Founder, Principal Pharmaceutical Inventor and CEO, Andira Pharmaceuticals, Vancouver, CanadaTitle: Addressing Synergy Versus Antagonism in Botanical-Based Pharmaceutical Development
Alexandros Makriyannis, Ph.D.
George D Behrakis Chair, Center for Drug Discovery, Northeastern University, Boston, MATitle: Structure and Function of the CB1 and CB2 Cannabinoid Receptor Targets for Novel Medications
Symposium III: "Nucleic Acids as Drugs, Drug Targets and Gene Editing Tools"
Co-Chairman : Troels Koch, M.Sc., Ph.D. Christine Esau, Ph.D.
Søren Warming, Ph.D.
Associate Director and Senior Scientist, Department Head, Molecular Biology, Genentech, Inc., San Francisco, CATitle: CRISPR Off-Target Analysis in Genetically Engineered Rodents
David Butler, Ph.D.
Vice President, Wave Life Sciences, Cambridge, MATitle: Control of backbone stereochemistry provides a new dimension for the optimization of oligonucleotide drug candidates
Norbert Pardi, Ph.D.
Research Assistant Professor of Medicine, University of Pennsylvania, Philadelphia, PATitle: Development of new generation vaccines using nucleoside-modified mRNA
Alexander McCampbell, Ph.D.
Senior Director, Principal Neurology Scientist, Biogen, Boston, MATitle: Antisense oligonucleotides as an emerging modality for the treatment of neuromuscular diseases
Andrea Kasinski, Ph.D.
William and Patty Miller Assistant Professor of Biological Sciences, Purdue University, West Lafayette, INTitle: Ligand-conjugated delivery of therapeutic microRNAs
Sven Korte, Ph.D.
Study Director, Covance Preclinical Services GmbH, Münster, GermanyTitle: Conduct and Design of Nonhuman Primate Studies for First in Man (FIM) and beyond. Oligos: Non Systemic Delivery – Rare and Orphan
Ourania M. Andrisani, Ph.D.
Professor, Purdue University College of Veterinary Medicine, West Lafayette, INTitle: MicroRNA Inhibitors Rescuing RNA Helicase DDX5 as Hepatitis B Virus (HBV) Antiviral and Anti-tumor Tools
David Evans, Ph.D.
Chief Scientific Officer, Sirnaomics Inc., Gaithersburg, MDTitle: Discovery and development of the novel RNAi therapeutics to treat cancer and fibrosis
Raman Bahal, Ph.D.
Department of Pharmaceutical Sciences, University of Connecticut, CTTitle: Next-generation Targeting of OncomiRs for Potential Cancer Therapy
John D. Lueck, Ph.D.
University of Rochester Medical Center, Rochester, NYTitle: Expanding the Genetic Code with Engineered tRNAs: Novel Therapies for Genetic Diseases
Symposium IV: "Drug Development for Infectious Disease and Immune Modulation"
Co-Chairman : Paul Dunman, Ph.D. Anna Jacobs, Ph.D.
Thomas Webster, Ph.D.
Department Chair, Chemical Engineering, Northeastern University, MATitle: Are Nanoparticles Suitable Drug Substitutes? Fighting Infection, Inhibiting Cancer, and Growing Tissues
Anna Jacobs, Ph.D.
Scientist, Walter Reed Army Institute of Research, Silver Spring, MDTitle: Bacteriophage and Antibiotic Combinations for the Treatment of Biofilm-Mediated Infections
Rachel Wozniak, MD, Ph.D.
Assistant Professor, Flaum Eye Institute, University of Rochester Medical Center, NYTitle: Development of a broad spectrum antimicrobial combination for the treatment of ocular infections
Cynthia Dowd, Ph.D.
Associate, Professor, Department of Chemistry, George Washington University, Washington, DCTitle: MEPicides as Promising Antimicrobials
Yan Yuan, Ph.D.
Professor, Department of Microbiology, University of Pennsylvania, Philadelphia, PATitle: An mTORC2 Inhibitor Reveals A Crucial Role of mTORC2 Signaling in Epstein-Barr Virus Lytic Replication and Tumorigenesis
Mu Yuguang, Ph.D.
Assoc. Prof., School of Biological Sciences, Nanyang Technological University, SingaporeTitle: Binding Modes of Teixobactin to Lipid II: Molecular Dynamics Study
Douglas K. Graham, MD, Ph.D.
Professor and Director, Aflac Cancer and Blood Disorders Center, Atlanta, GATitle: Transitioning Novel MerTK Small Molecule Inhibitors into Oncology Clinical Trials
Catherine Adamson, Ph.D.
Biomedical Sciences Research Complex, University of St Andrews, St Andrews, ScotlandTitle: Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice
Ryan Bennett, Ph.D.
Chief Scientific Officer, OyaGen, Inc., Rochester, NYTitle: Enabling APOBEC Innate Antiviral Immunity through HIV Vif Antagonists
Symposium V: "Oncology Drug Target Validation"
Co-Chairman : Yves Pommier, M.D., Ph.D. Liang Tong, Ph.D. Annette M. Tobia, Ph.D., JD
Elmar Nurmemmedov, Ph.D., MBA
Director of Drug Discovery, John Wayne Cancer Institute, Santa Monica, CATitle: Wnt Pathway: A Hallmark of Drug Discovery Challenge
Maria Kontoyianni, Ph.D.
Professor of Southern Illinois University Edwardsville, Edwardsville, ILTitle: A Computational Study on the Molecular Recognition and Plasticity of Cytochrome P450 3A4
Annette M. Tobia, Ph.D., JD
Founder and Chief Scientific Officer, Dynamis Pharmaceuticals, Inc., Jenkintown, PATitle: A Sugar-driven enzymatic pathway that results in inflammation and glycation and the effects of inhibiting it
Deborah W. Knapp, DVM, MS
Director, Purdue Comparative Oncology Program, Purdue University College of Veterinary Medicine, West Lafayette, INTitle: Advancing predictive modeling in cancer drug discovery through incorporation of naturally-occurring canine cancer models
Paul C. Trippier, Ph.D.
Dept. of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NETitle: Small Molecule AKR1C3 Inhibitors Counter Drug Resistance in Hematological and Solid Cancers
Paolo Lombardi, Ph.D.
Naxospharma S.R.L.Novate Milanese MI, Italy
Title: Berberine: an epiphany against cancer?
Liang Tong, Ph.D.
William R. Kenan, Jr. Professor, Department of Biological Sciences, Columbia University, New York, NYTitle: An allosteric mechanism for potent inhibition of human ATP-citrate lyase
Weike Mo, Ph.D.
Vice President, Digital China Health, Clinical and Genomic Data Services, ChinaTitle: Target Screening and Validation in SOC Resistant Cancer Organoids Models
Tinghu Zhang, Ph.D.
Lead Scientist, Dana-Farber Cancer Institute, Boston, MATitle: Degradation of CDK protein by PROTAC
Sathees C. Raghavan, Ph.D
Professor, Department of Biochemistry Indian Institute of Science Bangalore, IndiaTitle: BCL2 Specific Inhibitor, Disarib and Its Derivatives as a Potent Cancer Therapeutic Agent
Gregory M. Cresswell, Ph.D
Purdue University Center for Cancer Research, West Lafayette, INTitle: Targeting Myeloid Cells in the Tumor Microenvironment
